CB-5083 ATPase inhibitor targets p97 D2 domain to induce proteotoxic stress and apoptosis
Copy code to add this image to your page
The ubiquitin-proteasome system relies on specialized molecular machines to maintain intracellular protein quality control. Among these, p97—also designated valosin-containing protein (VCP)—operates as a homohexameric AAA+ ATPase that converts energy from ATP hydrolysis into mechanical force. This mechanical activity dislocates polyubiquitinated, misfolded substrates from organelle membranes, a process central to endoplasmic reticulum-associated degradation (ERAD). Structurally, each p97 subunit comprises an N-terminal domain responsible for cofactor binding, followed by two tandem ATPase domains designated D1 and D2. While the D1 domain predominantly governs hexamer assembly, the D2 domain supplies the primary catalytic power required for substrate translocation.
Disrupting this mechanical extraction machinery represents a direct therapeutic strategy against cancer cells reliant on elevated protein turnover. CB-5083 was developed as a first-in-class, orally bioavailable small molecule designed to selectively target the p97 hexamer. Pharmacological profiling established that the CB-5083 ATPase inhibitor acts via a reversible, ATP-competitive mechanism focused specifically on the catalytic pocket of the D2 domain. Binding to the D2 domain locks the hexameric ring structure, freezing the conformational transitions needed to pull polyubiquitinated polypeptides through the central pore. Under tested in vitro assay conditions, this targeted inhibition demonstrated nanomolar potency against purified p97 recombinant protein while showing negligible activity against unrelated kinases or adjacent AAA+ ATPases.
By blocking p97-mediated substrate dislocation, CB-5083 rapidly halts ERAD pathway kinetics. Polyubiquitinated proteins destined for proteasomal degradation instead accumulate within the endoplasmic reticulum membrane and cytosol. Biochemical analyses in treated cancer cell lines confirmed a swift, dose-dependent surge in high-molecular-weight ubiquitin conjugates. Cellular proteostasis collapses under this accumulated substrate burden. The physical strain placed on the endoplasmic reticulum membrane triggers activation of the three canonical branches of the unfolded protein response: PERK, IRE1, and ATF6.
Sustained UPR signaling shifts the physiological response from adaptive homeostasis to terminal apoptosis. Activation of the PERK pathway leads to phosphorylation of eIF2α, which suppresses general translation while selectively upregulating the transcription factor ATF4. Concurrently, activation of IRE1 leads to the unconventional splicing of XBP1 mRNA. Together, elevated ATF4 and spliced XBP1 induce transcription of the pro-apoptotic transcription factor CHOP (C/EBP homologous protein). Downstream CHOP expression suppresses anti-apoptotic BCL-2 family proteins while enhancing expression of BIM and PUMA. These mitochondrial events trigger cytochrome c release, apoptosome assembly, and sequential activation of caspase-9 and caspase-3. Downstream substrate cleavage proceeded rapidly. Proteolytic degradation of PARP confirms terminal execution of the apoptotic program.
Preclinical evaluation revealed pronounced antitumor responses across diverse tumor models possessing high basal proteotoxic stress. In human multiple myeloma cell lines—phenotypically sensitive to proteasome inhibition—CB-5083 suppressed cell proliferation with low nanomolar IC50 values. Similar antiproliferative activity was documented in patient-derived solid tumor models, including colorectal and pancreatic carcinoma cell lines. In rodent xenograft models, oral administration of CB-5083 achieved sustained target engagement, leading to intratumoral UPR activation, tumor regression, and prolonged survival without systemic weight loss.
Despite robust target engagement during Phase 1 clinical trials, therapeutic translation was ultimately compromised by unexpected ocular adverse events. Patients receiving oral CB-5083 reported visual disturbances, including dyschromatopsia and night blindness. Retinal toxicity studies revealed off-target inhibition of phosphodiesterase 6 (PDE6), an essential enzyme in retinal rod and cone phototransduction cascades. Chemical structural analysis identified that the quinazoline core of CB-5083 engaged the catalytic site of PDE6 alongside p97 D2. Although clinical progression of CB-5083 ceased due to this narrow therapeutic index, the compound provided unequivocal proof-of-concept for p97 inhibition in human oncology, establishing a structural baseline for second-generation p97 inhibitors designed without PDE6 cross-reactivity.
Mechanistic Efficacy and Pharmacological Limitations of p97 Inhibition
Copy code to add this image to your page
CB-5083 acts as an ATP-competitive inhibitor selectively targeting the D2 ATPase domain of the p97/VCP hexamer. By arresting p97-driven mechanical extraction of polyubiquitinated substrates during ERAD, the compound causes intracellular protein accumulation. Uncleared proteotoxic aggregates trigger acute ER stress and sustain UPR signal amplification, inducing CHOP-mediated apoptotic pathways in malignant phenotypes.
Targeted D2 Domain Inhibition Arrests ERAD and UPR
Biochemical assays confirm that CB-5083 selectively engages the p97 D2 ATPase domain, leaving the D1 domain structurally unaffected. This site-specific inhibition blocks the mechanical motor necessary to extract misfolded proteins from the endoplasmic reticulum membrane. Substrates targeted for proteasomal degradation linger in the lipid bilayer. Intracellular concentrations of polyubiquitinated conjugates rose dramatically within two hours of treatment in cultured carcinoma cells. The accumulating protein load induces severe ER membrane stress. Transmembrane stress sensors PERK, IRE1, and ATF6 undergo rapid auto-phosphorylation to initiate signaling cascades. Prolonged activation of these sensors elevates transcription of the pro-apoptotic protein CHOP. Apoptotic death follows within twelve hours. In mouse xenograft models bearing solid tumors, the CB-5083 ATPase inhibitor induced marked tumor growth delay at tolerated oral doses.
Off-Target PDE6 Cross-Reactivity Induces Retinal Photoreceptor Toxicity
Phase 1 clinical evaluation verified that oral administration achieved measurable target engagement in human tumor biopsies. Biomarkers of UPR activation, including spliced XBP1 and elevated CHOP transcription, confirmed p97 inhibition in vivo. However, human trials revealed unexpected visual symptoms ranging from impaired dark adaptation to color vision defects. Ocular toxicity assays linked these clinical observations to off-target inhibition of retinal PDE6 (IC50 = 210 nM). Photoreceptor signal transduction ceased in affected retinal tissues. Because PDE6 cross-reactivity could not be decoupled from the core scaffold of the molecule, clinical development was discontinued. These observations define critical binding determinants required to preserve p97 selectivity over retinal phosphodiesterases.